Anti IL-18 (GSK1070806) in Behcet's Disease

Summary

The primary outcome measure of the study is to demonstrate the safety and tolerability of GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease important secondary and exploratory outcomes.

Timeline

Start

2018-08-01

Primary completion

2020-04-01

Completion

2020-04-01

Drugs

Indications